0000904454-14-000398.txt : 20140501 0000904454-14-000398.hdr.sgml : 20140501 20140501194347 ACCESSION NUMBER: 0000904454-14-000398 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140501 FILED AS OF DATE: 20140501 DATE AS OF CHANGE: 20140501 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15 NEW ENGLAND EXECUTIVE PARK CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: 617-513-9882 MAIL ADDRESS: STREET 1: 15 NEW ENGLAND EXECUTIVE PARK CITY: BURLINGTON STATE: MA ZIP: 01803 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON DEVELOPMENT CORP ET AL CENTRAL INDEX KEY: 0000924020 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 14806603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: NJ FISCAL YEAR END: 1212 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 14806604 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 3 1 edgar.xml PRIMARY DOCUMENT X0206 3 2014-05-01 0 0001341235 Aldeyra Therapeutics, Inc. ALDX 0000200406 JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 0 0 1 0 0000924020 JOHNSON & JOHNSON DEVELOPMENT CORP ET AL ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 0 0 1 0 Series A Preferred Stock Common Stock 915366 I By Johnson & Johnson Development Corporation Non-Voting Series A Preferred Stock Common Stock 247694 I By Johnson & Johnson Development Corporation Series B Preferred Stock Common Stock 427591 I By Johnson & Johnson Development Corporation Non-Voting Series B Preferred Stock Common Stock 133827 I By Johnson & Johnson Development Corporation Series B Preferred Stock Warrant (Right to Buy) 2017-12-20 Common Stock 36345 I By Johnson & Johnson Development Corporation Series B Preferred Stock Warrant (Right to Buy) 2018-08-14 Common Stock 36345 I By Johnson & Johnson Development Corporation The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. All outstanding shares of the Issuer's preferred stock will automatically convert into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock will convert into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock will automatically convert into shares of Common Stock on a 1-for-1 basis. All outstanding warrants will be net exercised for shares of the Issuer's Series B Preferred Stock and subsequently will automatically convert into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock will automatically convert into shares of Common Stock on a 1-for-1 basis. Douglas Chia, Secretary of Johnson & Johnson 2014-05-01 Steven M. Rosenberg, Secretary of Johnson & Johnson Development Corporation 2014-05-01